Clinical Trials
17 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT06050512 2024-11-19
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT04864522 2023-11-21
MM FPBMC
University of Virginia
Phase 1/2 Withdrawn
NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05279859 2022-06-15
HERKULES-4
Erasca, Inc.
Phase 1/2 Withdrawn
NCT03873025 2021-08-17
PLACARD
University College, London
Phase 1/2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT03361319 2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT01174537 2015-06-11
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Hadassah Medical Organization
Phase 1/2 Withdrawn
NCT00378235 2014-11-13
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Withdrawn
NCT00776802 2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2 Withdrawn
NCT01340729 2013-04-05
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn